Evidence map›Paper›PMID 28090649›Full record

ArticleClinical pharmacology and therapeutics2017

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

J A Luzum, R E Pakyz, A R Elsey, C E Haidar, J F Peterson, M Whirl-Carrillo, S K Handelman, K Palmer, J M Pulley, M Beller and 20 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05669391 (Randomized Controlled Study on the Effect of Pharmacogenomics on Individualized Precise Treatment of Patients With Depression), which is not on this map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05669391 nacompletednot on this mapstarted 2023, after this paper: background citation

Randomized Controlled Study on the Effect of Pharmacogenomics on Individualized Precise Treatment of Patients With Depression

TypeinterventionalSponsorTongji UniversityRan2023 to 2024Enrolled120ConditionsPharmacogenomics, DepressionArmsGenomic analysis of antidepressants
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2024
    Review
  16. Article
  17. Impact of Pharmacogenomics in Clinical Practice.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

J A LuzumDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
R E PakyzProgram for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
A R ElseyDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
C E HaidarDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
J F PetersonDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
M Whirl-CarrilloStanford University School of Medicine, Palo Alto, California, USA.
S K HandelmanCenter for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
K PalmerProgram for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
J M PulleyVanderbilt Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
M BellerOffice of Research Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
J S SchildcroutDepartment of Statistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
J R FieldVanderbilt Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
K W WeitzelDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
R M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
L H CavallariDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
P H O'DonnellCenter for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
R B AltmanStanford University School of Medicine, Palo Alto, California, USA.
N PereiraDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
M J RatainCenter for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
D M RodenDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
P J EmbiDepartment of Biomedical Informatics, Ohio State University, Columbus, Ohio, USA.
W SadeeCenter for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
T E KleinStanford University School of Medicine, Palo Alto, California, USA.
J A JohnsonDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
M V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
L WangDepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
R M WeinshilboumDepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
A R ShuldinerProgram for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
R R FreimuthDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Pharmacogenomics Research Network Translational Pharmacogenetics Program

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GERARD PAUL ZAMBETTI · 1985 to 2026
$166.9M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M, JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
Mayo Clinic Center for Translational Science ActivitiesKL2RR024151 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$15.3M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
American Heart Association-American Stroke Association 14POST20100054CSRD VA I01 CX000363NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR001427NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA036401NCI NIH HHS R37 CA036401NCRR NIH HHS KL2 RR024151NHGRI NIH HHS U01 HG007269NHLBI NIH HHS L30 HL110279NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U19 HL065962NIGMS NIH HHS P50 GM115279NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS U01 GM061374NIGMS NIH HHS U01 GM061388NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01 GM092655NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.

Indexed as

Practice Guidelines as TopicAllelesDelivery of Health CareHumansNational Institutes of Health (U.S.)PharmacogeneticsTranslational Research, BiomedicalUnited States

Identifiers

PMID28090649
PMCPMC5511786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.